

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Berzofsky *et al.*

Application No. 10/532,374

Filed: April 21, 2005

Confirmation No. 4276

For: METHODS TO PREVENT TUMOR
RECURRENCE BY BLOCKADE OF TGF-
BETA

FILED VIA EFS

Examiner: Sheela J. Huff

Art Unit: 1643

Attorney Reference No. 4239-67016-02

FILED VIA ELECTRONIC FILING SYSTEM
UNITED STATES PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97(c)

Listed on the accompanying form PTO-1449 are four English-language documents (three of which are submitted herewith) and four non-English-language documents (all of which are submitted herewith). The four non-English-language documents were cited in an Office action for a corresponding Japanese application and correspond to the four cited English-language documents as follows:

Non-English-language Document	English Document
JP 2002-506613	WIPO 99/40220
JP 2003-528930	WIPO 01/74404
JP 2003-508755	WIPO 01/16604
JP 11-201967	U.S. Patent No. 6,855,507

Applicants respectfully request that these documents be listed as references cited on the issued patent.

This Information Disclosure Statement (IDS) is being mailed before Applicants received a final action, a notice of allowance, or an action that otherwise closes prosecution in the referenced application.

Copies of United States patents and United States published patent applications do not have to be provided to the Patent Office (37 C.F.R. 1.98(a)(2)(ii)). Copies of unpublished U.S. applications do not have to be provided, as long as the application is available on PAIR, as this requirement of 37 C.F.R. § 1.98(a)(2)(iii) has been waived by the United States Patent and Trademark Office pursuant to the Official Gazette Notice on October 19, 2004 (1287 OG 163). Applicants will provide copies of such patents or applications upon request.

A fee of \$180.00 is being electronically submitted herewith as required by 37 C.F.R. § 1.17(p) for filing this IDS in compliance with 1.97(c).

Please charge any additional fees which may be required in connection with filing this IDS, or credit any overpayment, to Deposit Account No. 02-4550.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 595-5300
Facsimile: (503) 595-5301

KLARQUIST SPARKMAN, LLP
By /Anne Carlson/
Anne Carlson, Ph.D.
Registration No. 47,472